- Home
- GDTC vs AIXI Comparison
GDTC vs AIXI Comparison
Compare GDTC & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- AIXI
- Stock Information
- Founded
- GDTC 2018
- AIXI 2001
- Country
- GDTC Singapore
- AIXI China
- Employees
- GDTC N/A
- AIXI N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- AIXI Computer Software: Prepackaged Software
- Sector
- GDTC Health Care
- AIXI Technology
- Exchange
- GDTC Nasdaq
- AIXI Nasdaq
- Market Cap
- GDTC 21.5M
- AIXI 31.2M
- IPO Year
- GDTC 2023
- AIXI 2023
- Fundamental
- Price
- GDTC $1.86
- AIXI $1.76
- Analyst Decision
- GDTC Buy
- AIXI
- Analyst Count
- GDTC 1
- AIXI 0
- Target Price
- GDTC $5.00
- AIXI N/A
- AVG Volume (30 Days)
- GDTC 18.1K
- AIXI 229.1K
- Earning Date
- GDTC 01-01-0001
- AIXI 05-15-2025
- Dividend Yield
- GDTC N/A
- AIXI N/A
- EPS Growth
- GDTC N/A
- AIXI N/A
- EPS
- GDTC N/A
- AIXI N/A
- Revenue
- GDTC $368,838.00
- AIXI $70,314,315.00
- Revenue This Year
- GDTC $5.37
- AIXI $26.84
- Revenue Next Year
- GDTC N/A
- AIXI N/A
- P/E Ratio
- GDTC N/A
- AIXI N/A
- Revenue Growth
- GDTC N/A
- AIXI 18.84
- 52 Week Low
- GDTC $1.20
- AIXI $1.77
- 52 Week High
- GDTC $4.05
- AIXI $8.31
- Technical
- Relative Strength Index (RSI)
- GDTC 35.89
- AIXI 36.26
- Support Level
- GDTC $1.85
- AIXI $1.76
- Resistance Level
- GDTC $1.95
- AIXI $2.36
- Average True Range (ATR)
- GDTC 0.10
- AIXI 0.24
- MACD
- GDTC -0.02
- AIXI -0.01
- Stochastic Oscillator
- GDTC 23.53
- AIXI 5.28
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.